LEO LUZNIK to Humans
This is a "connection" page, showing publications LEO LUZNIK has written about Humans.
Connection Strength
0.715
-
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia. Blood. 2024 Sep 12; 144(11):1168-1182.
Score: 0.019
-
This CAR won't start: predicting nonresponse in ALL. Blood Adv. 2023 08 08; 7(15):4215-4217.
Score: 0.018
-
Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight. Blood Rev. 2023 11; 62:101093.
Score: 0.017
-
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
Score: 0.017
-
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022 11 01; 132(21).
Score: 0.017
-
Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022 01 27; 139(4):608-623.
Score: 0.016
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
Score: 0.016
-
PTCy and "The Story of the Three Bears". Bone Marrow Transplant. 2021 04; 56(4):765-766.
Score: 0.015
-
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):513-521.
Score: 0.014
-
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019 11 21; 134(21):1802-1810.
Score: 0.014
-
PTCY keeps on giving! Blood. 2019 09 12; 134(11):848-849.
Score: 0.013
-
Post-transplantation cyclophosphamide for chimerism-based tolerance. Bone Marrow Transplant. 2019 08; 54(Suppl 2):769-774.
Score: 0.013
-
Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019 05 06; 129(6):2189-2191.
Score: 0.013
-
Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Semin Hematol. 2019 07; 56(3):221-226.
Score: 0.013
-
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2019 06; 25(6):1128-1135.
Score: 0.013
-
Have haploidentical transplants replaced umbilical cord transplants for acute leukemias? Curr Opin Hematol. 2018 03; 25(2):103-111.
Score: 0.012
-
Notching up B-cell pathology in chronic GVHD. Blood. 2017 11 09; 130(19):2053-2054.
Score: 0.012
-
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018 02; 24(2):343-352.
Score: 0.012
-
Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
Score: 0.011
-
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
Score: 0.011
-
For Whom the Bell Tolls: Programmed Death 1 as a Marker of Post-Transplantation Mortality. Biol Blood Marrow Transplant. 2016 12; 22(12):2115-2116.
Score: 0.011
-
Might haplo "be the (better) match"? Blood. 2016 Feb 18; 127(7):799-800.
Score: 0.010
-
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016 Apr; 53(2):90-7.
Score: 0.010
-
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
Score: 0.010
-
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016 Jan; 13(1):10-24.
Score: 0.010
-
Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Semin Hematol. 2015 Jul; 52(3):232-42.
Score: 0.010
-
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11; 124(25):3817-27.
Score: 0.010
-
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505.
Score: 0.009
-
Are alternative donors really still "alternative?". Biol Blood Marrow Transplant. 2014 Oct; 20(10):1463-4.
Score: 0.009
-
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013 Nov 13; 5(211):211ra157.
Score: 0.009
-
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012 Dec; 39(6):683-93.
Score: 0.008
-
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov; 17(6):493-9.
Score: 0.007
-
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul; 47(1-3):65-77.
Score: 0.007
-
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22; 115(16):3224-30.
Score: 0.007
-
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun; 14(6):641-50.
Score: 0.006
-
Finding the best way to train the immune system against lymphoma. Leuk Lymphoma. 2006 Apr; 47(4):577-9.
Score: 0.005
-
Chronic graft-versus-host disease: unresolved complication or ancient history? Blood. 2024 Sep 26; 144(13):1363-1373.
Score: 0.005
-
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 Apr; 5(4):601-624.
Score: 0.005
-
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Adv. 2023 09 12; 7(17):4886-4902.
Score: 0.004
-
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023 06 22; 141(25):3031-3038.
Score: 0.004
-
Nonmyeloablative alternative donor transplants. Curr Opin Oncol. 2003 Mar; 15(2):121-6.
Score: 0.004
-
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age =55 Years. Transplant Cell Ther. 2023 03; 29(3):182.e1-182.e8.
Score: 0.004
-
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 03; 29(3):208.e1-208.e6.
Score: 0.004
-
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplant Cell Ther. 2023 04; 29(4):267.e1-267.e5.
Score: 0.004
-
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. Br J Haematol. 2022 12; 199(5):720-727.
Score: 0.004
-
Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide. Blood Adv. 2022 09 13; 6(17):4994-5008.
Score: 0.004
-
Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma. 2022 12; 63(12):2987-2991.
Score: 0.004
-
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
Score: 0.004
-
Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002 Mar-Apr; 9(2):123-37.
Score: 0.004
-
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplant Cell Ther. 2022 05; 28(5):259.e1-259.e11.
Score: 0.004
-
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):260-269.
Score: 0.004
-
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629.
Score: 0.004
-
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplant Cell Ther. 2021 12; 27(12):1021.e1-1021.e5.
Score: 0.004
-
Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 11; 27(11):909.e1-909.e6.
Score: 0.004
-
Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. Transplant Cell Ther. 2021 10; 27(10):863.e1-863.e5.
Score: 0.004
-
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 06 20; 39(18):1971-1982.
Score: 0.004
-
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
Score: 0.004
-
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020 10 27; 4(20):5078-5088.
Score: 0.004
-
Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 12; 26(12):2306-2310.
Score: 0.004
-
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020 08 25; 4(16):3913-3925.
Score: 0.004
-
Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020 11; 26(11):2075-2081.
Score: 0.004
-
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV. 2020 09; 7(9):e602-e610.
Score: 0.004
-
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biol Blood Marrow Transplant. 2020 09; 26(9):1679-1688.
Score: 0.004
-
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 04 28; 4(8):1770-1779.
Score: 0.003
-
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
Score: 0.003
-
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia. 2020 06; 34(6):1563-1576.
Score: 0.003
-
Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant. 2020 03; 26(3):502-508.
Score: 0.003
-
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020 01; 105(1):47-58.
Score: 0.003
-
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
Score: 0.003
-
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
Score: 0.003
-
Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2431-2437.
Score: 0.003
-
Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020 01; 55(1):40-47.
Score: 0.003
-
Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. J Immunother. 2019 04; 42(3):73-80.
Score: 0.003
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019 04; 25(4):603-611.
Score: 0.003
-
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
Score: 0.003
-
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019 Apr; 6(4):e183-e193.
Score: 0.003
-
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020 01; 55(1):12-24.
Score: 0.003
-
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biol Blood Marrow Transplant. 2019 05; 25(5):868-882.
Score: 0.003
-
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018 11 02; 3(21).
Score: 0.003
-
Short telomere syndromes cause a primary T cell immunodeficiency. J Clin Invest. 2018 12 03; 128(12):5222-5234.
Score: 0.003
-
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biol Blood Marrow Transplant. 2018 10; 24(10):2056-2064.
Score: 0.003
-
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018 08 01; 24(15):3519-3527.
Score: 0.003
-
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1099-1102.
Score: 0.003
-
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1022-1028.
Score: 0.003
-
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018 05; 53(5):521-534.
Score: 0.003
-
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 06; 24(6):1274-1280.
Score: 0.003
-
Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 04; 24(4):666-677.
Score: 0.003
-
NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018 01 11; 131(2):247-262.
Score: 0.003
-
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1887-1894.
Score: 0.003
-
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1903-1909.
Score: 0.003
-
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017 03 09; 129(10):1389-1393.
Score: 0.003
-
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2017 Apr; 23(4):612-617.
Score: 0.003
-
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets. 2017; 18(3):315-331.
Score: 0.003
-
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
Score: 0.003
-
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
Score: 0.003
-
Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016 10; 30(10):2102-2106.
Score: 0.003
-
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016 Apr 12; 9:35.
Score: 0.003
-
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
Score: 0.003
-
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
Score: 0.003
-
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood. 2016 Jan 21; 127(3):352-9.
Score: 0.003
-
Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan; 22(1):112-8.
Score: 0.003
-
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
Score: 0.003
-
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2115-2122.
Score: 0.003
-
Localization of human immunodeficiency virus Rev in transfected and virus-infected cells. AIDS Res Hum Retroviruses. 1995 Jul; 11(7):795-804.
Score: 0.002
-
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
Score: 0.002
-
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20; 7(288):288ra78.
Score: 0.002
-
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
Score: 0.002
-
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
Score: 0.002
-
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016 Jan; 96(1):27-35.
Score: 0.002
-
Tat-independent replication of human immunodeficiency viruses. J Clin Invest. 1995 Jan; 95(1):328-32.
Score: 0.002
-
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
Score: 0.002
-
HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):314-8.
Score: 0.002
-
Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1514-7.
Score: 0.002
-
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013 Apr; 19(4):602-6.
Score: 0.002
-
Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013 Apr; 19(4):647-52.
Score: 0.002
-
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar; 19(3):481-5.
Score: 0.002
-
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
Score: 0.002
-
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
Score: 0.002
-
New treatment approaches in acute myeloid leukemia: review of recent clinical studies. Rev Recent Clin Trials. 2012 Aug; 7(3):224-37.
Score: 0.002
-
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
Score: 0.002
-
High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma. 2011 Nov; 52(11):2076-81.
Score: 0.002
-
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1404-9.
Score: 0.002
-
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011 May; 17(5):754-8.
Score: 0.002
-
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2011 Jan 13; 117(2):608-17.
Score: 0.002
-
Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2011 Jul; 46(7):1012-3.
Score: 0.002
-
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
Score: 0.002
-
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18; 115(11):2136-41.
Score: 0.002
-
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun; 21(6):1203-1210.
Score: 0.002
-
Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun; 43(12):969-70.
Score: 0.002
-
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar; 43(6):477-80.
Score: 0.002
-
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87.
Score: 0.002
-
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct; 42(8):523-7.
Score: 0.002
-
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep; 32(9):1439-47.
Score: 0.001
-
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct; 13(10):1185-91.
Score: 0.001
-
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr; 12(4):414-21.
Score: 0.001
-
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
Score: 0.001
-
A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol. 1996 Mar; 70(3):1596-601.
Score: 0.001